Experimental and clinical tests of FDA-approved kinase inhibitors for the treatment of neurological disorders (update 2024)
Since our previous summary of the 74 FDA-approved kinase inhibitors in clinical and preclinical trials for non-cancerous neurological treatment, the US FDA has approved 13 additional kinase inhibitors since early 2022. This update incorporates new evidence for the now 87 FDA-approved kinase inhibito...
Saved in:
| Main Authors: | Hassan Aliashrafzadeh, Dewey Liu, Samantha De Alba, Imad Akbar, Austin Lui, Jordan Vanleuven, Ryan Martin, Zhang Wang, Da Zhi Liu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration
2025-07-01
|
| Series: | Exploration of Drug Science |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/uploads/Article/A1008116/1008116.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Latest Update in Glaucoma: The first approvals for Rho Kinase inhibitors
by: Jatinder Bali, et al.
Published: (2020-04-01) -
FDA-approved kinase inhibitors in PROTAC design, development and synthesis
by: Kacper Kossakowski, et al.
Published: (2025-12-01) -
FDA-approved kinase inhibitors: a promising therapeutic avenue for traumatic brain injury
by: Dezhu Gao, et al.
Published: (2024-12-01) -
CAR T-cells meet autoimmune neurological diseases: a new dawn for therapy
by: Nikolaos A. Chinas, et al.
Published: (2025-07-01) -
The relationship between the levels of protein kinase C,thyroid hormone and neurological impairment and prognosis in patients with cerebral infarction
by: JIANG Dan,CHENG Hua,HE Xueling
Published: (2025-07-01)